Investigation of Chromatin Modifiers to Elucidate the Phenotypic Variability of Congenital Heart Disease in Patients with 22q11.2 Deletion Syndrome
Project Number1F30HL172604-01
Contact PI/Project LeaderMILLER, DANIELLA
Awardee OrganizationALBERT EINSTEIN COLLEGE OF MEDICINE
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT:
Congenital heart disease (CHD) presents a worldwide health burden as the most common type of congenital
abnormality, affecting ~1% of live births. While it remains the leading contributor to birth defect mortality, the
causes of CHD remain to be uncovered. Development of the heart is itself a complex process that is controlled
and regulated by multiple cell types, largely arising from the pharyngeal apparatus, a transient structure in
embryogenesis. The conotruncal region of the heart, composed of the outflow tract and great vessels, is
particularly susceptible to congenital anomalies since its formation and remodeling involve extensive
developmental processes. Conotruncal defects (CTDs) represent about 30% of all CHDs and occur in 40% of
patients with 22q11.2 deletion syndrome (22q11.2DS). TBX1, encoding a T-box transcription factor, is the main
causative gene for CTDs in 22q11.2DS, yet haploinsufficiency is not sufficient to explain the variable expressivity
of these defects. Therefore, 22q11.2DS represents a unique population in which to uncover genetic modifiers of
CTDs. To identify potentially damaging rare coding variants as modifiers, our lab performed whole genome
sequence analysis on 1,182 subjects with 22q11.2DS, with and without CHD. We found that chromatin regulatory
genes occurred in 8.5% of the 22q11.2DS subjects with CTDs. Some of these genes are also associated with
sporadic CHD in the general population, which is strongly suggestive that precise regulation of chromatin, and
consequently transcription, is essential for proper cardiac development. Our study aims to investigate the
interaction of chromatin regulatory genes, specifically Kmt2c and Kmt2d, with Tbx1 in mouse models. KMT2C
and KMT2D encode histone methyltransferases of the COMPASS family and they have also been implicated as
causative for sporadic CHD. I therefore hypothesize that Tbx1 and Kmt2c/d genetically interact in the
developmental processes critical for proper formation of the conotruncal region of the heart. To test this
interaction, I have generated mouse crosses for the conditional knockout of Kmt2c, Kmt2d, and Kmt2c/d in the
Tbx1 lineage. I will characterize cardiac defects through molecular and cellular approaches, as well as through
functional genomics studies that will delineate the shared and unique developmental roles of Kmt2c/d and Tbx1.
This will further the understanding of the genetic architecture of heart development and, consequently, the
etiology of CHD, knowledge of which will improve diagnosis and treatment.
Public Health Relevance Statement
PROJECT NARRATIVE:
In 22q11.2 deletion syndrome, around 60% of patients present with cardiac defects, largely due to a deletion
that includes TBX1; this provides a unique population in which to investigate possible genetic modifiers of
heart development. Our lab performed whole genome sequence analysis on human subjects and discovered a
subset of chromatin regulatory genes associated with heart defects in 22q11.2 deletion syndrome. This study
aims to determine the mechanism by which Tbx1 interacts with these chromatin regulatory genes,
particularly Kmt2c and Kmt2d, in mouse heart development.
No Sub Projects information available for 1F30HL172604-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1F30HL172604-01
Patents
No Patents information available for 1F30HL172604-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1F30HL172604-01
Clinical Studies
No Clinical Studies information available for 1F30HL172604-01
News and More
Related News Releases
No news release information available for 1F30HL172604-01
History
No Historical information available for 1F30HL172604-01
Similar Projects
No Similar Projects information available for 1F30HL172604-01